Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 1/20 | 0.45 |
| ▸ | PNMT | P11086 | 1/20 | 0.45 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.45 |
| ▸ | CNR1 | P21554 | 1/20 | 0.44 |
| ▸ | CNR2 | P34972 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14671446 | 0.88 | GLA (0.47) | DAOPNMTTAAR1SMN1; SMN2GLA | |
| SCHEMBL14402440 | 0.86 | HTR2A (0.48) | SMN1; SMN2GLASIGMAR1TP53HSD17B10 | |
| SCHEMBL18647948 | 0.85 | HTR2A (0.52) | SMN1; SMN2GLASIGMAR1TP53HSD17B10 | |
| SCHEMBL530150 | 0.83 | PNMT (0.45) | PNMTTAAR1CNR1CNR2SMN1; SMN2 | |
| SCHEMBL257081 | 0.83 | TSHR (0.44) | DAOPNMTTAAR1CNR2SMN1; SMN2 | |
| Ammonia Solution, Strong SCHEMBL6341561 | 0.82 | PNMT (0.44) | PNMTTAAR1CNR1CNR2SMN1; SMN2 | |
| SCHEMBL23850015 | 0.81 | TAAR1 (0.47) | DAOPNMTTAAR1CNR2SIGMAR1 | |
| Ammonia Solution, Strong SCHEMBL15468078 | 0.81 | TSHR (0.43) | DAOPNMTTAAR1CNR2SMN1; SMN2 | |
| SCHEMBL793707 | 0.81 | TAAR1 (0.69) | DAOPNMTTAAR1SMN1; SMN2GLA | |
| SCHEMBL530305 | 0.80 | CNR1 (0.48) | DAOCNR1CNR2SMN1; SMN2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230227429-A1 | SULPHONAMIDE COMPOUNDS | Anaxis Pharma Pty Ltd (AU) | 2023-07-20 | — | — | US | disclosed |
| US-20200247815-A1 | PYRAZOLYL-CONTAINING TRICYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF | SHANGHAI HANSOH BIOMEDICAL CO., LTD. (CN) | 2020-08-06 | — | — | US | disclosed |
| EP-2888247-A1 | SERINE/THREONINE KINASE INHIBITORS FOR THE TREATMENT OF HYPERPROLIFERATIVE!DISEASES | Array Biopharma, Inc. (US) | 2015-07-01 | — | — | EP | disclosed |
| WO-2014106019-A2 | NOVEL ANTIVIRAL AGENTS AGAINST HBV INFECTION | PHILADELPHIA HEALTH & EDUCATION CORPORATION, D/B/A DREXEL (US) | 2014-07-03 | — | — | WO | disclosed |
| WO-2014036015-A1 | SERINE/THREONINE KINASE INHIBITORS FOR THE TREATMENT OF HYPERPROLIFERATIVE|DISEASES | ARRAY BIOPHARMA INC. (US) | 2014-03-06 | — | — | WO | disclosed |
| US-20130123545-A1 | METHOD FOR SYNTHESIZING DIKETOPYRACENE | CANON KABUSHIKI KAISHA (JP) | 2013-05-16 | — | — | US | disclosed |
| US-20130072500-A1 | PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2013-03-21 | — | — | US | disclosed |
| US-8324221-B2 | Pyrimidyl cyclopentanes as Akt protein kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2012-12-04 | — | — | US | disclosed |
| US-20120122870-A1 | Treatment Of Ischemia-Reperfusion Injury | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2012-05-17 | — | — | US | disclosed |
| US-20120095004-A1 | Sphingosine Kinase Inhibitors | APOGEE BIOTECHNOLOGY CORPORATION (US) | 2012-04-19 | — | — | US | disclosed |
| WO-2012014908-A1 | METHOD FOR SYNTHESIZING DIKETOPYRACENE | CANON KABUSHIKI KAISHA (JP) | 2012-02-02 | — | — | WO | disclosed |
| US-8063248-B2 | 3-(4-Chloro-phenyl)-adamantane-1-carboxylic acidisopropylamide; antiproliferative, antiinflammatory agent, angiogenesis inhibitor; sphingolipid-derived signaling pathway; coupling acid or acylhalide of phenyl-adamantane derivatives with aminoalkyl-pyridine | APOGEE BIOTECHNOLOGY CORPORATION (US) | 2011-11-22 | — | — | US | disclosed |
| WO-2011032277-A1 | QUINAZOLINONE DERIVATIVES AS VIRAL POLYMERASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-03-24 | — | — | WO | disclosed |
| US-20110053959-A1 | PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2011-03-03 | — | — | US | disclosed |
| US-7741345-B2 | AZA-peptide protease inhibitors | GILEAD SCIENCES, INC. (US) | 2010-06-22 | — | — | US | disclosed |
| WO-2009152166-A1 | [1,2,4]THIADIAZINE 1,1-DIOXIDE COMPOUNDS | ANADYS PHARMACEUTICALS, INC. (US) | 2009-12-17 | — | — | WO | disclosed |
| US-7557110-B2 | MAPKAP-K2; inflammatory disease, autoimmune disease, destructive bone disorder, cancer and/or tumour growth; 5-[(trans-4-aminocyclohexyl)amino]-3-fluoro-6-methyl(pyrazolo[1,5-a]pyri- midin-7-yl)}(4-iodophenyl)amine | TEIJIN PHARMA LIMITED (JP) | 2009-07-07 | — | — | US | disclosed |
| US-20080167352-A1 | Sphingosine Kinase Inhibitors | APOGEE BIOTECHNOLOGY CORPORATION (US) | 2008-07-10 | — | — | US | disclosed |
| US-7338961-B2 | Sphingosine kinase inhibitors | APOGEE BIOTECHNOLOGY CORPORATION (US) | 2008-03-04 | — | — | US | disclosed |
| US-20070032531-A1 | SPHINGOSINE KINASE INHIBITORS AND METHODS OF THEIR USE | APOGEE BIOTECHNOLOGY CORPORATION (US) | 2007-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130123545-A1 | METHOD FOR SYNTHESIZING DIKETOPYRACENE | DHPS, CBR1, DDT | DAO 228/4885PNMT 1650/4885TAAR1 3044/4885 |
| US-20070032531-A1 | SPHINGOSINE KINASE INHIBITORS AND METHODS OF THEIR USE | SPHK1, SPHK2, S1PR2 | DAO 3290/4885PNMT 2784/4885TAAR1 4180/4885 |
| US-20230227429-A1 | SULPHONAMIDE COMPOUNDS | MLKL, RIPK3, CASP1 | DAO 2100/4885PNMT 3802/4885TAAR1 4199/4885 |
| US-20120095004-A1 | Sphingosine Kinase Inhibitors | SPHK1, SPHK2, S1PR1 | DAO 2361/4885PNMT 2888/4885TAAR1 2190/4885 |
| US-20110053959-A1 | PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | AKT1, AKT2, PIK3CA | DAO 2394/4885PNMT 2091/4885TAAR1 4116/4885 |
| US-20120122870-A1 | Treatment Of Ischemia-Reperfusion Injury | SPHK1, SPHK2, S1PR2 | DAO 3427/4885PNMT 2604/4885TAAR1 2452/4885 |
| US-20080167352-A1 | Sphingosine Kinase Inhibitors | SPHK1, SPHK2, S1PR1 | DAO 2361/4885PNMT 2888/4885TAAR1 2190/4885 |
| US-20200247815-A1 | PYRAZOLYL-CONTAINING TRICYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF | MAPK1, MAPK11, MAPK14 | DAO 2790/4885PNMT 3395/4885TAAR1 4503/4885 |
| US-20130072500-A1 | PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | PIK3CA, AKT1, AKT2 | DAO 2274/4885PNMT 2111/4885TAAR1 4006/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.